MedTrace Logo

PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients

NCT03029858 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2017-01-24

No results posted yet for this study

Summary

The study will investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor （EGFR）T790M positive advanced NSCLC patients. In addition, we will explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.

Conditions

  • Small Cell Lung Cancer, Polygonal Type

Interventions

OTHER

No interventions will be taken in this Observational study

TAGRISSO(osimertinib/AZD9291）

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Shun Lu, M.D · Shanghai Chest hospital of Shanghai Jiaotong University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03029858 on ClinicalTrials.gov